Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study ; volume:15 ; number:4 ; day:1 ; month:3 ; year:2024 ; pages:869-881 ; date:4.2024
Diabetes therapy ; 15, Heft 4 (1.3.2024), 869-881, 4.2024
- Creator
-
Roy Chowdhury, Sharmistha
Sadouki, Fethi
Collins, Edward
Keen, Frederick
Bhagi, Ridhi
Lim, Yuan S. J.
Cozma, Silviu L.
Bain, Stephen C.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s13300-024-01551-4
- URN
-
urn:nbn:de:101:1-2405211137299.944470419008
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.20252025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Roy Chowdhury, Sharmistha
- Sadouki, Fethi
- Collins, Edward
- Keen, Frederick
- Bhagi, Ridhi
- Lim, Yuan S. J.
- Cozma, Silviu L.
- Bain, Stephen C.
- SpringerLink (Online service)
Other Objects (12)
Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients
Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?
Semaglutide
Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study
Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom
Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment
Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population
Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany
The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark
Adult-onset sporadic chorea: real-world data from a single-centre retrospective study
Aortic versus axillary artery cannulation for hemiarch replacement: single-centre real-world experience
Real-World Treatment Patterns Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide
Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients
Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?
Semaglutide
Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study
Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom
Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment
Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population
Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany
The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark
Adult-onset sporadic chorea: real-world data from a single-centre retrospective study
Aortic versus axillary artery cannulation for hemiarch replacement: single-centre real-world experience
Real-World Treatment Patterns Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide
Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients
Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?
Semaglutide
Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study
Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom
Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment
Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population
Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany
The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark
Adult-onset sporadic chorea: real-world data from a single-centre retrospective study
Aortic versus axillary artery cannulation for hemiarch replacement: single-centre real-world experience